ライフサイエンスコーパス: hydroxychloroquine

1 us etanercept or MTX plus sulfasalazine plus hydroxychloroquine).

2 c arrhythmia among the patients who received hydroxychloroquine.

3 herapy, most commonly low-dose prednisone or hydroxychloroquine.

4 Similar results were obtained with hydroxychloroquine.

5 r risk was observed among patients receiving hydroxychloroquine.

6 ify potentially effective dosing regimens of hydroxychloroquine.

7 or coronavirus disease 2019 with chloroquine/hydroxychloroquine.

8 oteins which was reversed by the addition of hydroxychloroquine.

9 were assigned to receive remdesivir, 954 to hydroxychloroquine, 1411 to lopinavir (without interfero

10 with mortality in the control group (9.3%), hydroxychloroquine (18.0%; hazard ratio 1.335, 95% CI 1.

11 Patients who received hydroxychloroquine (200mg tid dosage for 10 days) on a c

12 With hydroxychloroquine, 4 hospitalizations occurred plus 1 n

13 y completed study evaluating the efficacy of hydroxychloroquine 400 mg daily to prevent the recurrenc

14 All patients received hydroxychloroquine (400 mg twice daily for 10 days) beca

15 Patients were randomly assigned to hydroxychloroquine (400 mg twice daily for 2 doses, then

16 Hydroxychloroquine (400 mg/d for 3 days followed by 200

17 Patients were randomized (1:1) to receive hydroxychloroquine (400 mg/d) or placebo until week 24.

18 Hydroxychloroquine, 400 mg, or matching placebo once dai

19 significantly between participants receiving hydroxychloroquine (49 of 414 [11.8%]) and those receivi

20 Compared with the control group (0.3%), hydroxychloroquine (6.1%; 2.369, 1.935-2.900), hydroxych

21 follow-up of 22.5 days, 811 (58.9%) received hydroxychloroquine (600 mg twice on day 1, then 400 mg d

22 91% received hydroxychloroquine, 66% azithromycin, 3% remdesivir, 21%

23 8%), calcineurin inhibitor withdrawal (23%), hydroxychloroquine (71%), antibiotics (74%), tocilizumab

24 ed participants to receive either placebo or hydroxychloroquine (800 mg once, followed by 600 mg in 6

25 Oral hydroxychloroquine (800 mg once, followed by 600 mg in 6

26 Patients received hydroxychloroquine (84%), azithromycin (75%), augmented

27 xate, thiopurines, anti-TNFs, sulfasalazine, hydroxychloroquine, abatacept, or rituximab after the in

28 cells as well as whether the chloroquine or hydroxychloroquine actually inhibit the autophagy.

29 efit, triple therapy, with sulfasalazine and hydroxychloroquine added to methotrexate, was noninferio

30 id-19 who had been admitted to the hospital, hydroxychloroquine administration was not associated wit

31 usted OR, 2.13 [95% CI, 1.12-4.05]), but not hydroxychloroquine alone (adjusted OR, 1.91 [95% CI, 0.9

32 azithromycin (HR, 1.35 [95% CI, 0.76-2.40]), hydroxychloroquine alone (HR, 1.08 [95% CI, 0.63-1.85]),

33 scale at 15 days was not affected by either hydroxychloroquine alone (odds ratio, 1.21; 95% confiden

34 n was 189/735 (25.7% [95% CI, 22.3%-28.9%]), hydroxychloroquine alone, 54/271 (19.9% [95% CI, 15.2%-2

35 of both hydroxychloroquine and azithromycin, hydroxychloroquine alone, azithromycin alone, or neither

36 roquine alone, chloroquine with a macrolide, hydroxychloroquine alone, or hydroxychloroquine with a m

37 d with mild-to-moderate Covid-19, the use of hydroxychloroquine, alone or with azithromycin, did not

38 els were more frequent in patients receiving hydroxychloroquine, alone or with azithromycin, than in

39 Hydroxychloroquine, an essential treatment for many pati

40 6 contacts were randomly assigned to receive hydroxychloroquine and 1198 to receive usual care.

41 e randomly assigned 1561 patients to receive hydroxychloroquine and 3155 to receive usual care.

42 e primary analysis; 38 patients treated with hydroxychloroquine and 46 patients treated with SOCalone

43 226) posits that the use of a combination of hydroxychloroquine and azithromycin as an outpatient tre

44 when evaluating the evidence for or against hydroxychloroquine and azithromycin bitherapy.

45 Hydroxychloroquine and azithromycin have been used to tr

46 Receipt of both hydroxychloroquine and azithromycin, hydroxychloroquine

47 unosuppression reduction and the addition of hydroxychloroquine and azithromycin.

48 All hospitalized patients received hydroxychloroquine and azithromycin.

49 treated with combination group (chloroquine/hydroxychloroquine and azithromycin; 440.6+/-24.9 versus

50 Hydroxychloroquine and chloroquine are used extensively

51 Hydroxychloroquine and chloroquine have antiviral effect

52 Hydroxychloroquine and chloroquine have been proposed as

53 We used the definition for hydroxychloroquine and chloroquine toxicity provided by

54 for treatment of immune-mediated conditions, hydroxychloroquine and chloroquine, have recently attrac

55 aseline, there was no difference between the hydroxychloroquine and control groups in SARS-CoV-2 acqu

56 xamine carefully not only what we know about hydroxychloroquine and COVID-19 but also how we learned

57 P = 0.50), in 104 of 947 patients receiving hydroxychloroquine and in 84 of 906 receiving its contro

58 Hydroxychloroquine and low-dose aspirin may have a prote

59 rity over 14 days did not differ between the hydroxychloroquine and placebo groups (difference in sym

60 ays did not significantly differ between the hydroxychloroquine and placebo groups (median [IQR] scor

61 e propose that the lysosomotropic effects of hydroxychloroquine and several other drugs undergoing te

62 Hydroxychloroquine and sulfasalazine are compatible with

63 no correlation between cord blood levels of hydroxychloroquine and the neonatal QTc (R=0.02, P=0.86)

64 Results were similar in the hydroxychloroquine and usual-care groups with respect to

65 ) received chloroquine, 191 (95.0%) received hydroxychloroquine, and 119 (59.2%) also received azithr

66 lable for 61 patients (13 chloroquine, three hydroxychloroquine, and 45 quinine).

67 chloroquine with a macrolide, 3016 received hydroxychloroquine, and 6221 received hydroxychloroquine

68 orioretinopathy, maculopathy associated with hydroxychloroquine, and healthy eyes) were studied.

69 feron beta, corticosteroids, chloroquine and hydroxychloroquine, and ivermectin) under evaluation for

70 Although chloroquine, hydroxychloroquine, and quinine are used for a range of

71 Finally, an autophagy inhibitor, hydroxychloroquine, approved for use in pregnant women,

72 hy associated with the use of chloroquine or hydroxychloroquine are not undergoing routine monitoring

73 The data suggest that doxycycline and hydroxychloroquine are primarily independent bacteriosta

74 Different dosage regimens of hydroxychloroquine are used to manage coronavirus diseas

75 Subjects were identified with hydroxychloroquine as a medication by electronic query a

76 ssociated most strongly with the presence of hydroxychloroquine as defined by mfERG testing.

77 A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID

78 e excluded a clinically meaningful effect of hydroxychloroquine as postexposure prophylaxis to preven

79 he United States and parts of Canada testing hydroxychloroquine as postexposure prophylaxis.

80 of 400 mg twice daily, or standard care plus hydroxychloroquine at a dose of 400 mg twice daily plus

81 to receive standard care, standard care plus hydroxychloroquine at a dose of 400 mg twice daily, or s

82 us etanercept or MTX plus sulfasalazine plus hydroxychloroquine) at week 24 if the DAS28-ESR was >/=

83 nificantly more likely in patients receiving hydroxychloroquine + azithromycin (adjusted OR, 2.13 [95

84 ferences in mortality for patients receiving hydroxychloroquine + azithromycin (HR, 1.35 [95% CI, 0.7

85 probability of death for patients receiving hydroxychloroquine + azithromycin was 189/735 (25.7% [95

86 Eighty percent received hydroxychloroquine +/- azithromycin.

87 Patients with COVID-19 positive who received hydroxychloroquine+/-azithromycin across 13 hospitals be

88 ave shown a potential benefit of chloroquine/hydroxychloroquine+/-azithromycin for the treatment of c

89 spitalized patients treated with chloroquine/hydroxychloroquine+/-azithromycin from March 1 to the 23

90 Hydroxychloroquine+/-azithromycin have been widely used

91 Sixty-seven (1.03%) had hydroxychloroquine+/-azithromycin held or discontinued d

92 ospitalized patients with COVID-19 receiving hydroxychloroquine+/-azithromycin therapy.

93 Of these patients, hydroxychloroquine+/-azithromycin were discontinued in 5

94 19 patients to date treated with chloroquine/hydroxychloroquine+/-azithromycin, no instances of Torsa

95 ospitalized patients with COVID-19 receiving hydroxychloroquine+/-azithromycin.

96 All patients were treated with hydroxychloroquine, azithromycin, and low-molecular-weig

97 Treatment for COVID-19 included frequently hydroxychloroquine, azithromycin, high-dose steroids, lo

98 male, median age, 63 years), those receiving hydroxychloroquine, azithromycin, or both were more like

99 litan New York with COVID-19, treatment with hydroxychloroquine, azithromycin, or both, compared with

100 l involvement in short- and long-term use of hydroxychloroquine before the development of retinopathy

101 All patients were prescribed hydroxychloroquine between weeks 24 and 48.

102 nique opportunity in which neonatal ECGs and hydroxychloroquine blood levels were available in a rece

103 These cases show that high doses of hydroxychloroquine can initiate the development of retin

104 Whether hydroxychloroquine can prevent symptomatic infection aft

105 S pharmacy data to compare prescriptions for hydroxychloroquine/chloroquine and azithromycin in Febru

106 ts with primary Sjogren syndrome, the use of hydroxychloroquine compared with placebo did not improve

107 ot taking antiretroviral therapy, the use of hydroxychloroquine compared with placebo did not reduce

108 ratory illness from COVID-19, treatment with hydroxychloroquine, compared with placebo, did not signi

109 tration, which is similar to the free plasma hydroxychloroquine concentration.

110 ion members among 2361 patients who had used hydroxychloroquine continuously for at least 5 years acc

111 m non-randomized studies have suggested that hydroxychloroquine could be an effective therapeutic age

112 everal studies found that patients receiving hydroxychloroquine developed a QTc interval of 500 ms or

113 spitalized with Covid-19, those who received hydroxychloroquine did not have a lower incidence of dea

114 -risk or moderate-risk exposure to Covid-19, hydroxychloroquine did not prevent illness compatible wi

115 Postexposure therapy with hydroxychloroquine did not prevent SARS-CoV-2 infection

116 Hydroxychloroquine did not substantially reduce symptom

117 o standard of care treatment (which included hydroxychloroquine) did not improve clinical outcomes.

118 Chloroquine and hydroxychloroquine exert beneficial effects in experimen

119 Hydroxychloroquine exposure is low and cannot be predict

120 irus transmission by direct contact, whereas hydroxychloroquine failed as prophylaxis.

121 developed retinal toxic effects after using hydroxychloroquine for a mean of 10.4 years (range, 3-19

122 nts with the pericentral pattern were taking hydroxychloroquine for a somewhat longer duration (19.5

123 ical trial testing high-dose (1000 mg daily) hydroxychloroquine for advanced non-small cell lung canc

124 use, and 1409 (7.8%) had used chloroquine or hydroxychloroquine for at least 4 years.

125 , weight, start date, or dosing; or (3) took hydroxychloroquine for malaria prophylaxis.

126 nd colleagues report the results of trial of hydroxychloroquine for patients presenting with nonsever

127 Data on the efficacy of hydroxychloroquine for the treatment of coronavirus dise

128 These findings do not support the use of hydroxychloroquine for treatment of COVID-19 among hospi

129 phagy stimulator (Tunicamycin) or inhibitor (Hydroxychloroquine) functionally proved that autophagy w

130 andomly assigned clusters of contacts to the hydroxychloroquine group (which received the drug at a d

131 e primary end point was 17.9% (10/56) in the hydroxychloroquine group and 17.2% (11/64) in the placeb

132 omization, 25 of 241 patients (10.4%) in the hydroxychloroquine group and 25 of 236 (10.6%) in the pl

133 , there were 2 serious adverse events in the hydroxychloroquine group and 3 in the placebo group; in

134 omly assigned: 337 (407 participants) to the hydroxychloroquine group and 334 (422 participants) to t

135 , there were 3 serious adverse events in the hydroxychloroquine group and 4 in the placebo group.

136 days occurred in 421 patients (27.0%) in the hydroxychloroquine group and in 790 (25.0%) in the usual

137 Viral load increased in the hydroxychloroquine group compared with placebo (0.61 log

138 ients reported influenza-like illness in the hydroxychloroquine group compared with the placebo group

139 anical ventilation at baseline, those in the hydroxychloroquine group had a higher frequency of invas

140 All but 1 patient in the hydroxychloroquine group had detectable blood levels of

141 ncidence of adverse events was higher in the hydroxychloroquine group than in the usual-care group (5

142 xperiencing adverse events was higher in the hydroxychloroquine group than the control group (66 [16.

143 [95% CI, -1.6 to 3.3] in the clarithromycin-hydroxychloroquine group vs. the placebo group); the sco

144 The enrollment of patients in the hydroxychloroquine group was closed on June 5, 2020, aft

145 The results suggest that patients in the hydroxychloroquine group were less likely to be discharg

146 (95% CI, 34.2 to 37.1) in the clarithromycin-hydroxychloroquine group, and 34.8 (95% CI, 33.4 to 36.2

147 doxycycline group, 96 in the clarithromycin-hydroxychloroquine group, and 98 in the placebo group).

148 group and 6.00 (2.52) to 5.94 (2.40) in the hydroxychloroquine group.

149 group and 6.53 (1.97) to 6.22 (1.87) in the hydroxychloroquine group.

150 group and 5.09 (3.06) to 4.59 (2.90) in the hydroxychloroquine group.

151 ratory and observational data suggested that hydroxychloroquine had biological activity against SARS-

152 Hydroxychloroquine had no efficacy in patients with anti

153 s, 24% (49 of 201) of participants receiving hydroxychloroquine had ongoing symptoms compared with 30

154 The TLR7 to TLR9 blocker hydroxychloroquine has been in use in patients with lupu

155 Hydroxychloroquine has been proposed as a postexposure t

156 Hydroxychloroquine has been widely administered to patie

157 cularly for people with conditions for which hydroxychloroquine has demonstrated benefits in preventi

158 s have been widely discussed: remdesivir and hydroxychloroquine (HCQ) + azithromycin (AZ).

159 gated the role of either Chloroquine (CQ) or Hydroxychloroquine (HCQ) alone or in combination with az

160 ect antimalarial responsiveness, and whether hydroxychloroquine (HCQ) and quinacrine (QC) differentia

161 Hydroxychloroquine (HCQ) appears to be a promising treat

162 Chloroquine (CQ) and hydroxychloroquine (HCQ) are on the World Health Organiz

163 Chloroquine (CQ) and hydroxychloroquine (HCQ) are used to treat auto-immune r

164 tudy the adherence of rheumatologists to the hydroxychloroquine (HCQ) dosing guidelines established b

165 t autophagy blockade via chloroquine (CQ) or hydroxychloroquine (HCQ) enhanced the efficacy of MEK-ER

166 the lysomotropic drugs chloroquine (CQ) and hydroxychloroquine (HCQ) have been widely investigated,

167 nt case-control study suggested a benefit of hydroxychloroquine (HCQ) in lowering the risk of cardiac

168 thalmology recommendations for screening for hydroxychloroquine (HCQ) retinopathy advise objective me

169 ations on screening for chloroquine (CQ) and hydroxychloroquine (HCQ) retinopathy are revised in ligh

170 lysosomotropic agent and autophagy inhibitor hydroxychloroquine (HCQ) synergizes with CCI-779 and led

171 Finally, we discuss hydroxychloroquine (HCQ) use by asymptomatic subjects wh

172 Hydroxychloroquine (HCQ) was used by 78.1% of respondent

173 ed to determine whether early treatment with hydroxychloroquine (HCQ) would be more efficacious than

174 In contrast, the autophagy inhibitors hydroxychloroquine (HCQ), 3-methyladenine (3-MA), and ba

175 Administration of hydroxychloroquine (HCQ), a small molecule inhibitor of

176 Hydroxychloroquine (HCQ), an orally administered Toll-li

177 vitro data led to the significant uptake of hydroxychloroquine (HCQ), and to lesser extent chloroqui

178 re underway combining anticancer agents with hydroxychloroquine (HCQ), but concentrations of HCQ requ

179 palbociclib (PAL) and an autophagy inhibitor hydroxychloroquine (HCQ), we demonstrate a ratiometrical

180 isk factors should help physicians prescribe hydroxychloroquine in a manner that will minimize the li

181 sk of unfavorable outcomes was observed with hydroxychloroquine in comparison to standard of care.

182 Randomized, controlled trials of hydroxychloroquine in patients with Covid-19 are needed.

183 tine use of azithromycin in combination with hydroxychloroquine in patients with severe COVID-19.

184 help determine whether there is a place for hydroxychloroquine in the treatment of Covid-19.

185 Hydroxychloroquine-induced pigmentation is not a rare ad

186 Hydroxychloroquine-induced pigmentation is not a rare ad

187 Our data support the hypothesis that hydroxychloroquine-induced pigmentation is secondary to

188 articipants into 2 groups: those affected by hydroxychloroquine-induced retinal toxicity and those un

189 Early detection of hydroxychloroquine-induced retinopathy is known to preve

190 e inner retina appears not to be involved in hydroxychloroquine-induced retinopathy to any clinically

191 enolate mofetil, plasmapheresis, colchicine, hydroxychloroquine, intravenous immunoglobulin, nonstero

192 rovide reassurances that the maternal use of hydroxychloroquine is associated with a low incidence of

193 on and limited reports on clinical efficacy, hydroxychloroquine is being considered as prophylaxis an

194 Although hydroxychloroquine is generally considered safe during p

195 Hydroxychloroquine is the most frequently prescribed imm

196 Hydroxychloroquine is thought to inhibit growth of C. bu

197 ia, and despite completing a 5-day course of hydroxychloroquine, later developed marked inflammatory

198 our repurposed antiviral drugs - remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a -

199 These remdesivir, hydroxychloroquine, lopinavir, and interferon regimens h

200 ith tocilizumab, intravenous immunoglobulin, hydroxychloroquine, lopinavir/ritonavir, and broad-spect

201 Two retrospective analyses suggest that hydroxychloroquine may prevent congenital heart block in

202 l at baseline than those who did not receive hydroxychloroquine (median ratio of partial pressure of

203 er between patients treated with chloroquine/hydroxychloroquine (monotherapy group) versus those trea

204 ing and insufficient regarding the effect of hydroxychloroquine on such outcomes as all-cause mortali

205 then baseline testing and the first dose of hydroxychloroquine or ascorbic acid, was a median of 2 d

206 nts referred to the University of Ottawa for hydroxychloroquine or chloroquine retinopathy screening

207 Evidence on the benefits and harms of using hydroxychloroquine or chloroquine to treat COVID-19 is v

208 ultinational registry analysis of the use of hydroxychloroquine or chloroquine with or without a macr

209 Hydroxychloroquine or chloroquine, often in combination

210 We were unable to confirm a benefit of hydroxychloroquine or chloroquine, when used alone or wi

211 Treatment with a specific FXa inhibitor, hydroxychloroquine or fluvastatin significantly reduced

212 use of remdesivir, or off-label drug use of hydroxychloroquine or other therapies.

213 rapy with the addition of sulfasalazine plus hydroxychloroquine (or etanercept, if necessary, after 6

214 atic drugs (methotrexate, sulfasalazine, and hydroxychloroquine) or etanercept plus methotrexate.

215 triple therapy (MTX plus sulfasalazine plus hydroxychloroquine), or step-up from MTX monotherapy to

216 l course of doxycycline, clarithromycin plus hydroxychloroquine, or placebo.

217 tive Approach to Congenital Heart Block With Hydroxychloroquine [PATCH]; NCT01379573).

218 White and coauthors discuss chloroquine and hydroxychloroquine pharmacology in the context of possib

219 xplain inhibition of TLR7 and 9 signaling by hydroxychloroquine (Plaquenil; Sanofi-Aventis, Bridgewat

220 ce interval [CI], 0.69 to 2.11; P = 1.00) or hydroxychloroquine plus azithromycin (odds ratio, 0.99;

221 TE) and a 12-month course of doxycycline and hydroxychloroquine prophylaxis in patients with signific

222 in COVID-19 treatment (lopinavir/ritonavir, hydroxychloroquine, remdesivir, and tocilizumab) were as

223 PDA with the combination of trametinib plus hydroxychloroquine resulted in a partial, but nonetheles

224 ars implies the need to reassess the risk of hydroxychloroquine retinopathy (HR) in obese women using

225 ocal placoid pigment epitheliopathy (n = 1), hydroxychloroquine retinopathy (n = 1), and macular tela

226 Hydroxychloroquine retinopathy does not always develop i

227 Twenty-seven percent of cases of hydroxychloroquine retinopathy in obese women had ostens

228 Patients with hydroxychloroquine retinopathy involving the retinal pig

229 These data suggest that hydroxychloroquine retinopathy is more common than previ

230 The overall prevalence of hydroxychloroquine retinopathy was 7.5% but varied with

231 Clinical findings in patients with hydroxychloroquine retinopathy were monitored with repea

232 Of 201 total patients (18% Asian) with hydroxychloroquine retinopathy, 153 (76%) had typical pa

233 res and long-term follow-up of patients with hydroxychloroquine retinopathy, making it difficult to s

234 sted to recognize pericentral and parafoveal hydroxychloroquine retinopathy.

235 hy, early retinopathy, or moderate or severe hydroxychloroquine retinopathy.

236 New therapeutic agents such as statins, hydroxychloroquine, rituximab, complement inhibitors, an

237 s, we discuss the candidate therapies, i.e., hydroxychloroquine, rituximab, eculizumab, sirolimus, an

238 Of patients presenting for hydroxychloroquine screening, 54.8% of patients received

239 red or white fields should be acceptable for hydroxychloroquine screening, as long as the clinician i

240 With white 10-2 visual field hydroxychloroquine screening, the use of pattern deviati

241 % maximal effective concentration values for hydroxychloroquine should be compared to the in vivo fre

242 l treatments, including convalescent plasma, hydroxychloroquine, steroids, and/or tocilizumab.

243 Pharmacokinetic modeling of hydroxychloroquine suggested that the total lung exposur

244 Hydroxychloroquine sulfate is widely used for the long-t

245 Hydroxychloroquine sulfate retinopathy can progress afte

246 endations, long-term users of chloroquine or hydroxychloroquine sulfate should undergo regular visits

247 inopathy is a known risk of long-term use of hydroxychloroquine sulfate.

248 Decline in CD4 cell count was greater in the hydroxychloroquine than placebo group (-85 cells/muL vs

249 1.0 indicating more favorable outcomes with hydroxychloroquine than placebo.

250 Side effects were more common with hydroxychloroquine than with placebo (40.1% vs. 16.8%),

251 a cutanea tarda benefit from iron depletion, hydroxychloroquine therapy, and, if applicable, eliminat

252 d future clinical trials involving high-dose hydroxychloroquine to improve safety monitoring and pres

253 Our data on hydroxychloroquine (together with previous reports in ma

254 brane carries a positive prognostic value in hydroxychloroquine toxic effects because it may be assoc

255 Early recognition of hydroxychloroquine toxic effects before any fundus chang

256 Relative foveal resistance in hydroxychloroquine toxic effects was supported by this c

257 Given the infrequent occurrence of hydroxychloroquine toxic effects, few data are available

258 itivity and specificity for the detection of hydroxychloroquine toxicity as identified by mfERG, and

259 New hydroxychloroquine toxicity was found in 2 of 183 return

260 uding 12 with chloroquine toxicity, one with hydroxychloroquine toxicity, and 25 with quinine toxicit

261 ily dosing is a cost-effective way to reduce hydroxychloroquine toxicity, but height, weight, and dai

262 Hydroxychloroquine-treated patients were more severely i

263 Mean age and duration of hydroxychloroquine treatment did not differ statisticall

264 ean age, 55.7+/-10.4 years; mean duration of hydroxychloroquine treatment, 15.0+/-7.5 years) were div

265 there was no significant association between hydroxychloroquine use and intubation or death (hazard r

266 We examined the association between hydroxychloroquine use and intubation or death at a larg

267 Hydroxychloroquine use for at least 5 years.

268 Patients' amount of chloroquine or hydroxychloroquine use in the 5 years since the initial

269 nts, each additional month of chloroquine or hydroxychloroquine use was associated with a 2.0% increa

270 Hydroxychloroquine use was not predictive.

271 .1%) had at least 1 record of chloroquine or hydroxychloroquine use, and 1409 (7.8%) had used chloroq

272 focal parafoveal thinning, a toxic effect of hydroxychloroquine use.

273 Hydroxychloroquine used for treating systemic lupus eryt

274 -fold higher antiproliferative activity than hydroxychloroquine used in clinical trials.

275 tinal thickness between short- and long-term hydroxychloroquine users (n = 27) in different retinal r

276 Among chloroquine or hydroxychloroquine users and those at high risk for toxi

277 e was seen in the SD-OCT images of long-term hydroxychloroquine users until the actual appearance of

278 its in >/=3 of 5 years) among chloroquine or hydroxychloroquine users, including those at highest ris

279 neonatal QTc (R=0.02, P=0.86) or the mean of hydroxychloroquine values obtained throughout each indiv

280 in 43% (92 of 212) of participants receiving hydroxychloroquine versus 22% (46 of 211) receiving plac

281 2.77-9.77), and receipt of azithromycin plus hydroxychloroquine (vs treatment with neither: 2.93, 1.7

282 Although hydroxychloroquine was assessed as being non-dialyzable,

283 In addition, hydroxychloroquine was not associated with a lower incid

284 nt, antimetabolite was discontinued and only hydroxychloroquine was started.

285 8 (35.7%), the dose was reduced, in 2 (7.1%) hydroxychloroquine was stopped, but in 16 (57.1%) no act

286 evels, use of glucocorticoids, and nonuse of hydroxychloroquine were all significantly associated wit

287 QT interval (QTc) measurement, and levels of hydroxychloroquine were assessed during each trimester o

288 eatment of mice with the autophagy inhibitor hydroxychloroquine, which is currently being used in sev

289 We studied retrospectively 13 patients using hydroxychloroquine who had undergone both red (FASTPAC)

290 red to patients without contraindications to hydroxychloroquine who received SOCalone.

291 ew was performed to identify patients taking hydroxychloroquine who were screened for toxic effects f

292 0%; hazard ratio 1.335, 95% CI 1.223-1.457), hydroxychloroquine with a macrolide (23.8%; 1.447, 1.368

293 droxychloroquine (6.1%; 2.369, 1.935-2.900), hydroxychloroquine with a macrolide (8.1%; 5.106, 4.106-

294 ceived hydroxychloroquine, and 6221 received hydroxychloroquine with a macrolide) and 81 144 patients

295 th a macrolide, hydroxychloroquine alone, or hydroxychloroquine with a macrolide), and patients who r

296 e compared outcomes in patients who received hydroxychloroquine with those in patients who did not, u

297 d hamsters with a low dose of favipiravir or hydroxychloroquine with(out) azithromycin resulted in, r

298 Hydroxychloroquine, with or without azithromycin, has be

299 early results-such as those associated with hydroxychloroquine-with caution as we only begin to unde

300 hromycin to standard of care, which included hydroxychloroquine, would improve clinical outcomes of p